Stryker Debt to Equity Ratio 2006-2018 | SYK
Current and historical debt to equity ratio values for Stryker (SYK) over the last 10 years. The debt/equity ratio can be defined as a measure of a company's financial leverage calculated by dividing its long-term debt by stockholders' equity. Stryker debt/equity for the three months ending September 30, 2018 was 0.60.
| Stryker Debt/Equity Ratio Historical Data | |||
|---|---|---|---|
| Date | Long Term Debt | Shareholder's Equity | Debt to Equity Ratio |
| 2018-09-30 | $5.93B | $9.86B | 0.60 |
| 2018-06-30 | $5.93B | $9.46B | 0.63 |
| 2018-03-31 | $5.92B | $9.22B | 0.64 |
| 2017-12-31 | $6.59B | $9.98B | 0.66 |
| 2017-09-30 | $6.59B | $10.43B | 0.63 |
| 2017-06-30 | $6.59B | $10.04B | 0.66 |
| 2017-03-31 | $7.18B | $9.70B | 0.74 |
| 2016-12-31 | $6.69B | $9.55B | 0.70 |
| 2016-09-30 | $6.71B | $9.33B | 0.72 |
| 2016-06-30 | $6.72B | $9.10B | 0.74 |
| 2016-03-31 | $6.71B | $8.81B | 0.76 |
| 2015-12-31 | $3.23B | $8.51B | 0.38 |
| 2015-09-30 | $2.51B | $8.48B | 0.30 |
| 2015-06-30 | $3.24B | $8.51B | 0.38 |
| 2015-03-31 | $3.26B | $8.32B | 0.39 |
| 2014-12-31 | $3.25B | $8.60B | 0.38 |
| 2014-09-30 | $3.23B | $8.62B | 0.38 |
| 2014-06-30 | $3.24B | $9.00B | 0.36 |
| 2014-03-31 | $2.24B | $9.06B | 0.25 |
| 2013-12-31 | $2.74B | $9.05B | 0.30 |
| 2013-09-30 | $2.74B | $8.74B | 0.31 |
| 2013-06-30 | $2.74B | $8.60B | 0.32 |
| 2013-03-31 | $2.74B | $8.46B | 0.32 |
| 2012-12-31 | $1.75B | $8.60B | 0.20 |
| 2012-09-30 | $1.75B | $8.36B | 0.21 |
| 2012-06-30 | $1.75B | $7.95B | 0.22 |
| 2012-03-31 | $1.75B | $8.02B | 0.22 |
| 2011-12-31 | $1.75B | $7.68B | 0.23 |
| 2011-09-30 | $1.76B | $7.56B | 0.23 |
| 2011-06-30 | $1.00B | $7.78B | 0.13 |
| 2011-03-31 | $1.00B | $7.45B | 0.13 |
| 2010-12-31 | $1.00B | $7.17B | 0.14 |
| 2010-09-30 | $1.00B | $7.31B | 0.14 |
| 2010-06-30 | $1.00B | $6.75B | 0.15 |
| 2010-03-31 | $1.00B | $6.67B | 0.15 |
| 2009-12-31 | $0.00B | $6.60B | 0.00 |
| 2009-09-30 | $0.00B | $6.44B | 0.00 |
| 2009-06-30 | $0.00B | $6.06B | 0.00 |
| 2009-03-31 | $0.00B | $5.63B | 0.00 |
| 2008-12-31 | $0.00B | $5.41B | 0.00 |
| 2008-09-30 | $0.00B | $5.75B | 0.00 |
| 2008-06-30 | $0.00B | $6.22B | 0.00 |
| 2008-03-31 | $0.00B | $5.93B | 0.00 |
| 2007-12-31 | $0.00B | $5.38B | 0.00 |
| 2007-09-30 | $0.00B | $5.16B | 0.00 |
| 2007-06-30 | $0.00B | $4.80B | 0.00 |
| 2007-03-31 | $0.00B | $4.49B | 0.00 |
| 2006-12-31 | $0.00B | $4.19B | 0.00 |
| 2006-09-30 | $0.00B | $3.99B | 0.00 |
| 2006-06-30 | $0.00B | $3.77B | 0.00 |
| 2006-03-31 | $0.10B | $3.49B | 0.03 |
| 2005-12-31 | $0.18B | $3.30B | 0.06 |
| 2005-09-30 | $0.00B | $3.11B | 0.00 |
| 2005-06-30 | $0.00B | $2.99B | 0.00 |
| 2005-03-31 | $0.00B | $2.90B | 0.00 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Products Manufacturing | $62.096B | $12.444B |
| Stryker Corporation is one of the world's leading medical technology companies and together with its customers, is driven to make healthcare better. The company offers innovative products and services in Orthopaedics, Medical and Surgical, and Neurotechnology and Spine that help improve patient and hospital outcomes. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Medtronic (MDT) | Ireland | $124.463B | 18.51 |
| Abbott Laboratories (ABT) | United States | $121.292B | 24.58 |
| Boston Scientific (BSX) | United States | $47.118B | 23.81 |
| Baxter (BAX) | United States | $34.153B | 22.06 |
| Zimmer Biomet Holdings (ZBH) | United States | $22.927B | 14.87 |
| Smith & Nephew SNATS (SNN) | United Kingdom | $15.749B | 0.00 |
| ResMed (RMD) | United States | $14.479B | 27.61 |
| Perrigo (PRGO) | Ireland | $8.210B | 12.46 |
| Bio-Rad Laboratories (BIO) | United States | $7.933B | 50.72 |
| Canopy Growth (CGC) | Canada | $7.466B | 0.00 |
| Hill-Rom Holdings (HRC) | United States | $6.097B | 19.08 |
| Aurora Cannabis (ACB) | Canada | $5.815B | 31.74 |
| Haemonetics (HAE) | United States | $5.279B | 46.42 |
| ICU Medical (ICUI) | United States | $4.777B | 26.62 |
| Insulet (PODD) | United States | $4.449B | 0.00 |
| Hutchison China MediTech (HCM) | China | $4.244B | 0.00 |
| Agios Pharmaceuticals (AGIO) | United States | $3.828B | 0.00 |
| GW Pharmaceuticals (GWPH) | United Kingdom | $3.656B | 0.00 |
| Neogen (NEOG) | United States | $3.174B | 48.06 |
| NuVasive (NUVA) | United States | $3.162B | 29.43 |
| National Vision Holdings (EYE) | United States | $2.783B | 53.82 |
| Quidel (QDEL) | United States | $2.312B | 30.14 |
| Aphria (APHA) | $2.200B | 0.00 | |
| NxStage Medical (NXTM) | United States | $1.933B | 0.00 |
| Phibro Animal Health (PAHC) | United States | $1.381B | 19.54 |
| AtriCure (ATRC) | United States | $1.208B | 0.00 |
| Cardiovascular Systems (CSII) | United States | $1.049B | 1511.50 |
| VAREX IMAGING (VREX) | United States | $0.923B | 18.53 |
| OraSure Technologies (OSUR) | United States | $0.783B | 44.10 |
| Meridian Bioscience (VIVO) | United States | $0.780B | 24.86 |
| Surmodics (SRDX) | United States | $0.738B | 112.75 |
| PetIQ (PETQ) | United States | $0.733B | 20.83 |
| Cerus (CERS) | United States | $0.710B | 0.00 |
| Eagle Pharmaceuticals (EGRX) | United States | $0.709B | 22.76 |
| MacroGenics (MGNX) | United States | $0.706B | 0.00 |
| Omeros (OMER) | United States | $0.632B | 0.00 |
| Lantheus Holdings (LNTH) | United States | $0.616B | 19.06 |
| LeMaitre Vascular (LMAT) | United States | $0.533B | 26.19 |
| Owens & Minor (OMI) | United States | $0.525B | 5.94 |
| NanoString Technologies (NSTG) | United States | $0.506B | 0.00 |
| Insys Therapeutics (INSY) | United States | $0.480B | 0.00 |
| TG Therapeutics (TGTX) | United States | $0.405B | 0.00 |
| Evolus (EOLS) | United States | $0.378B | 0.00 |
| Quanterix (QTRX) | United States | $0.370B | 0.00 |
| Utah Medical Products (UTMD) | United States | $0.344B | 22.27 |
| Cytosorbents (CTSO) | United States | $0.309B | 0.00 |
| Neptune Technologies & Bioresources Inc (NEPT) | Canada | $0.248B | 0.00 |
| Surface Oncology (SURF) | United States | $0.227B | 0.00 |
| Rockwell Medical (RMTI) | United States | $0.199B | 0.00 |
| Bovie Medical (BVX) | United States | $0.195B | 0.00 |
| BioLife Solutions (BLFS) | United States | $0.193B | 261.25 |
| Chimerix (CMRX) | United States | $0.167B | 0.00 |
| Fonar (FONR) | United States | $0.137B | 6.90 |
| Conatus Pharmaceuticals (CNAT) | United States | $0.135B | 0.00 |
| Imprimis Pharmaceuticals (IMMY) | United States | $0.113B | 0.00 |
| Chembio Diagnostics (CEMI) | United States | $0.104B | 0.00 |
| United-Guardian (UG) | United States | $0.079B | 16.64 |
| Female Health (VERU) | United States | $0.073B | 0.00 |
| Oramed Pharmaceuticals (ORMP) | Israel | $0.072B | 0.00 |
| InfuSystems Holdings (INFU) | United States | $0.066B | 0.00 |
| Trinity Biotech (TRIB) | Ireland | $0.061B | 19.53 |
| CAS Medical Systems (CASM) | United States | $0.053B | 0.00 |
| Neurotrope (NTRP) | United States | $0.047B | 0.00 |
| ImmuCell (ICCC) | United States | $0.041B | 0.00 |
| Capricor Therapeutics (CAPR) | United States | $0.026B | 0.00 |
| Myomo (MYO) | United States | $0.022B | 0.00 |
| Akers Biosciences Inc (AKER) | United States | $0.020B | 0.00 |
| InVivo Therapeutics Holdings (NVIV) | United States | $0.018B | 0.00 |
| Senestech (SNES) | United States | $0.015B | 0.00 |
| Cellectar Biosciences (CLRB) | United States | $0.010B | 0.00 |
| Valeritas Holdings (VLRX) | United States | $0.010B | 0.00 |
| NeuroMetrix (NURO) | United States | $0.007B | 0.00 |
